Meteorism and intestinal air in infants: simethicone, and clinical results
There is a moment, in the first weeks of life, when crying seems to have no logic. The baby is fed, dry, soothed… yet they stiffen, pull their knees to their chest, stop and start again like a wave. For parents it is a night that stretches on. For those who work in the world of nutrition and medical devices it is a recurring question: what really works when the problem is (also) gas?
Infant colic is a functional disorder, often self-limiting, but not for this reason “minor.” It affects sleep, breastfeeding, family anxiety. And when the dominant symptom is abdominal distension, meteorism or that feeling of a “belly full of air,” simethicone almost always enters the conversation.
Simethicone: what it does and what it does not do
Simethicone is a silicone compound that acts as a non-systemic surfactant: it reduces the surface tension of gas bubbles in the gastrointestinal tract, promoting their aggregation and dispersion. In practice, it helps microbubbles “come together” and be eliminated more easily through belching or flatulence. It is an important detail: it does not decrease gas production, but makes its removal easier.
This characteristic also explains its safety profile: simethicone is not absorbed to a significant extent and is eliminated in the feces. Reported adverse events are rare and generally mild (for example nausea or diarrhea). The main contraindication remains hypersensitivity to the active ingredient.
Why formulation matters more than it seems
In treating gas-related symptoms, the focus is often on “what” and less on “how.” Yet the vehicle can change the story: dispersion, residence time, behavior in water or in emulsions such as milk.
In this sense, the Rilefast works on a simple concept: maximizing the antifoam effect of simethicone by using an olive oil suspension, designed for better dispersion even in “difficult” contexts such as dairy-based feeding. The logic is practical even before it is chemical: if a product has to fit into a newborn’s routine, it must perform well exactly where it is used.
In antifoam tests conducted with standardized methodology (ASTM E2407-04), the formulation shows marked activity both in water and in milk, with a dispersion dynamic that supports the action of simethicone when the medium is not “simple.” It is a technical point, but with a concrete effect: when the goal is to break down excess microbubbles, the ability to distribute uniformly can make a difference in the perception of relief.
When numbers tell the everyday story
Evidence becomes truly interesting when it does not stop at “it seems to work,” but tries to measure. In the case of Rilefast, the clinical data move on multiple levels, with different tools, but converging.
After two weeks, symptom reduction was clear: pain and bloating decrease by up to about 88%, while aerophagia and belching fall by about 76% and 86% respectively. These percentages, translated into simple words, mean less abdominal tension and less “air that remains trapped,” with a direct impact on comfort.
Measuring the gas
The second level of evidence is even more concrete because it tries to “see” the gas, not only describe it. In an investigation on 40 newborns, the presence of intestinal air was assessed by ultrasound before treatment and after 14 days of simethicone combined with silicon dioxide.
The LAAM distance (between the aorta and the linea alba), used as an indicator of gas content, decreases significantly (p<0.0001). At the same time, colic episodes recorded by caregivers decrease markedly both at the end of treatment and after discontinuation, maintaining significance (p<0.0001). In addition, a clear link emerges: when LAAM is greater, colic tends to be more frequent as well; as days pass, both values decrease.
A further multicenter retrospective evaluation on 63 patients between 2 and 6 weeks confirms improvement from the point of view of post-feeding pain. After 14 days of treatment with an oral formulation containing simethicone and silicon dioxide, the NIPS (Neonatal Infant Pain Scale) drops from 5.03 ± 1.36 to 1.22 ± 1.45 (p<0.001). In other words: fewer signs of pain and less distress. The effect is more evident in newborns with more intense initial symptoms, while in formula-fed babies the improvement appears more limited.
Three different perspectives – questionnaires, caregiver diary, ultrasound, pain scales – tell the same thing: working on the “behavior” of gas can translate into a benefit that is noticeable, and measurable, in everyday life.
Two modes of use, one priority: simplicity
To turn a rationale into a result, therapy must be feasible. This is where formats matter: not only for convenience, but for adherence.
Rilefast CE Drops: a single dose of 20 drops provides 40 mg of simethicone, with directions for use that can be adapted according to age and need.
Rilefast CE Spray: a single dose of 5 actuations provides 40 mg of simethicone, with a delivery method designed to simplify administration and make the gesture quicker.
Both fall within the scope of MDR-certified medical devices, with a formulation approach that combines simethicone and functional components, and with safety and biocompatibility checks consistent with the intended use.
A concrete answer in an area still full of unmet need
In the world of infant colic, frustration often comes from uncertainty: many hypotheses, few certainties, long timelines. Yet when the picture is dominated by air and distension, the antifoam approach remains one of the most rational paths, especially if supported by clinical data and coherent formulation design.
Rilefast CE fits here: not as a “miracle” promise, but as a platform ready for commercialization, with clear positioning, regulatory compliance and results that speak the language of clinical practice. For those looking for solutions in private label or CDMO, being able to rely on usage protocols and measured outcomes means shortening the distance between idea and market, without giving up credibility.
Source: “Simethicone” StatPearls (NCBI Bookshelf)
